Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance.
Martinez-Balibrea E, Martínez-Cardús A, Ginés A, Ruiz de Porras V, Moutinho C, Layos L, Manzano JL, Bugés C, Bystrup S, Esteller M, Abad A. Martinez-Balibrea E, et al. Among authors: manzano jl. Mol Cancer Ther. 2015 Aug;14(8):1767-76. doi: 10.1158/1535-7163.MCT-14-0636. Epub 2015 Jul 16. Mol Cancer Ther. 2015. PMID: 26184483 Review.
Resistant mechanisms to BRAF inhibitors in melanoma.
Manzano JL, Layos L, Bugés C, de Los Llanos Gil M, Vila L, Martínez-Balibrea E, Martínez-Cardús A. Manzano JL, et al. Ann Transl Med. 2016 Jun;4(12):237. doi: 10.21037/atm.2016.06.07. Ann Transl Med. 2016. PMID: 27429963 Free PMC article. Review.
Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients.
Ruiz de Porras V, Bystrup S, Cabrero-de Las Heras S, Musulén E, Palomero L, Alonso MH, Nieto R, Arango D, Moreno V, Queralt C, Manzano JL, Layos L, Bugés C, Martinez-Balibrea E. Ruiz de Porras V, et al. Among authors: manzano jl. Cancers (Basel). 2019 Oct 11;11(10):1540. doi: 10.3390/cancers11101540. Cancers (Basel). 2019. PMID: 31614664 Free PMC article.
Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway.
Ruiz de Porras V, Bystrup S, Martínez-Cardús A, Pluvinet R, Sumoy L, Howells L, James MI, Iwuji C, Manzano JL, Layos L, Bugés C, Abad A, Martínez-Balibrea E. Ruiz de Porras V, et al. Among authors: manzano jl. Sci Rep. 2016 Apr 19;6:24675. doi: 10.1038/srep24675. Sci Rep. 2016. PMID: 27091625 Free PMC article.
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
Martinez-Balibrea E, Abad A, Martínez-Cardús A, Ginés A, Valladares M, Navarro M, Aranda E, Marcuello E, Benavides M, Massutí B, Carrato A, Layos L, Manzano JL, Moreno V. Martinez-Balibrea E, et al. Among authors: manzano jl. Br J Cancer. 2010 Aug 10;103(4):581-9. doi: 10.1038/sj.bjc.6605776. Epub 2010 Jul 13. Br J Cancer. 2010. PMID: 20628391 Free PMC article. Clinical Trial.
Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.
Abad A, Carrato A, Navarro M, Sastre J, Cervantes A, Antón A, Martinez-Villacampa M, Marcuello E, Massutí B, Aranda E, Manzano JL, Guallar JL, Diaz-Rubio E. Abad A, et al. Among authors: manzano jl. Clin Colorectal Cancer. 2005 Mar;4(6):384-9. doi: 10.3816/ccc.2005.n.010. Clin Colorectal Cancer. 2005. PMID: 15807931 Clinical Trial.
Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.
Santos C, Azuara D, Garcia-Carbonero R, Alfonso PG, Carrato A, Elez ME, Gomez A, Losa F, Montagut C, Massuti B, Navarro V, Varela M, Lopez-Doriga A, Moreno V, Valladares M, Manzano JL, Vieitez JM, Aranda E, Sanjuan X, Tabernero J, Capella G, Salazar R. Santos C, et al. Among authors: manzano jl. Mol Cancer Ther. 2017 Sep;16(9):1999-2007. doi: 10.1158/1535-7163.MCT-17-0153. Epub 2017 Jun 16. Mol Cancer Ther. 2017. PMID: 28626084 Free article.
137 results